IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

MONKEY POX; A REEMERGENT DISEASE

Gauri G. Gaikawad*, Anuradha M. Jadhav, Prajakta J. Shingote, Mangesh Rode, Priyanka Rode, Ruturaj Chavan, Amir Shaikh
Shri. Chanakya Education Society's Indira College of Pharmacy, Pune 411033. PDEA's Shankarrao Ursal College of Pharmaceutical sciences and Research Centre, Kharadi, Pune

Abstract
As the most significant orthopoxvirus infection in humans in the smallpox post-eradication era, monkeypox is an emerging zoonotic disease. Monkey pox has a clinical appearance that is comparable to smallpox's. Monkeypox has a case fatality rate of 10%, which is in between variola major's case fatality rate of 30% and variola minor's case fatality rate of 1%. Although the disease is indigenous to the Democratic Republic of the Congo, incidences of monkeypox in humans and wildlife have been reported in other Central and West African nations. Additionally, the sickness was once brought into the USA. Although the condition has long been thought to be uncommon and self-limiting, new isolated reports suggest otherwise. Unfortunately, the data that has been gathered is little, scattered, and frequently inaccurate. Consequently, the goal of this review is to Locate all cases of human monkeypox that have been reported, as well as any pertinent epidemiological data. There are enormous gaps in our knowledge of the origin, epidemiology, and ecology of the illness, which have led to an increase in the frequency and geographic distribution of human monkeypox cases in recent years. The monkeypox virus is regarded as a high danger pathogen that causes a disease that is significant for public health. In order to plan effective preventative, preparedness, and response actions, it is vital to concentrate on developing surveillance capacities that will yield meaningful information.

***Keywords*: Orthopoxvirus, zoonotic disease.**

INTRODUCTION

A member of the Poxviradea family of Orth poxviruses, monkeypox is a developing zoonotic disease that affects people. It is reported to have a complicated double-stranded DNA. In smallpox post eradication locations, human monkeypox infection is seen. The monkeypox virus is capable of infecting mammals, including humans. The monkeypox virus's natural host is still mostly unknown, however it has been isolated twice from wild animals, once from a sooty mangabey in Côte d'Ivoire and once from a ropy squirrel in the Democratic Republic of the Congo. When transmitted from person to person, the monkeypox virus takes 12 days to incubate.

The monkeypox virus possesses morphologic characteristics that are comparable to those of other Orth poxviruses, including a size range of 200–250 nm, an enclosed brick-shaped virus with surface tubules and a dumbbell-shaped core component. The monkeypox virus's core region, which codes for structural proteins and vital enzymes, shares 96.3% of its genome with the variola virus but differs significantly from the part of the genome that codes for virulence factors and host range factors. Monkeypox has a case fatality rate between 3.4 and 10%, which is between variola major and minor, which have case fatality rates of 1% and 30%, respectively.

Monkeypox viruses have been divided into two clades: the Central African clade and the West African clade. The latter has a case fatality rate of 11% and human-to-human transmission has been confirmed in the Central African clade, whereas the former has a case fatality rate of 1% and no reports of human-to-human transmission. The virus thought to be responsible for the US outbreak was the West African variation, and the virus thought to be responsible for the Democratic Republic of the Congo outbreak was the Central African form. In comparison to the West African clade, it has been found that the Central African clade, also known as the Congo basin clade, is linked to higher rates of morbidity and mortality, human-to-human transmission, and viremia. Additionally, adults in the US were significantly.

The Democratic Republic of the Congo is where the disease originated, and there, the first case was noted in 1970. Monkeypox has, however, been linked to several human and animal cases in Central and West Africa. As protection against smallpox vaccine is dwindling, the number of cases of the human monkeypox virus has increased in recent years, along with an increase in the geographic distribution of the illness. With a 6% fatality rate, Nigeria had the greatest monkeypox virus outbreak in the West African subclade in 2017. In September 2018, two cases of monkeypox

were brought into the UK via Nigerian citizens, and one of those cases led to nosocomial infections that affected healthcare personnel. Additionally, the virus that causes monkeypox was brought into the United States.

The monkeypox virus was first discovered in monkeys, but it also naturally infects tree squirrels, rope squirrels, Gambian pouched rats, and dormice. The monkeypox virus was first discovered in monkeys, but it also naturally infects tree squirrels, rope squirrels, Gambian pouched rats, and dormice.[4]The monkeypox virus is a severe threat to life in the Democratic Republic of the Congo, West and Central Africa, and perhaps even globally, while having a low propensity to transmit among humans. The monkeypox virus carries a high risk due to its potential to create a disease that has significant public health implications. After the eradication of smallpox, the World Health Organization (WHO) designated the monkeypox virus as the most significant orthopoxviral infection in humans. As a result, surveillance is necessary. Although there is presently no proof that human-to-human transmission may keep the monkeypox virus alive in local populations, a study implies that frequent contact with monkeypox-infected animals in a community with weak herd immunity can lead to huge clusters of people carrying the virus.



Fig. 1 symptoms of monkeypox

Fig. 2 monkeypox virus

EPIDEMIOLOGY

The West African clade of the monkeypox virus is thought to be less virulent than the Congo Basin clade, which both cause disease.

Contrary to its name, the monkeypox virus has never been isolated from any species of monkey and has only ever been isolated once from a wild animal, a Funiculus squirrel in the Democratic Republic of the Congo. The virus has proven infectious among a wide variety of numerous mammalian species. As a result, the WHO is considering taking action to rename the illness in order to remove any negative connotations, similar to how COVID-19 was renamed. To pinpoint the precise viral reservoir and its wild circulation, more investigation is required.

Although contact with wild animals has been linked to human infections, the precise exposure mechanism has been challenging to determine, especially in regions where contact with animals may have occurred through domestic rodent infestations, hunting, or the preparation of bushmeat for domestic consumption. It has been established that transmission can take place by contact with lesion exudate, crust material, or infected animals' faeces, as well as through saliva and respiratory excretions. However, it is less effective than that seen with smallpox. Prior research suggests that family

members or those who care for a monkeypox patient are at a higher risk of contracting the virus. Family members who had not received the smallpox vaccine had a higher risk of contracting the illness than those who had.

In West Africa, the first incidence of human monkeypox was documented in 1970. Consequently, the Congo Basin in Central Africa has seen the majority of reported illnesses. Depending on the lineage, mortality ranges from 3-6% to 17%, and children, pregnant women, and those with impaired immune systems are more vulnerable to negative effects. 2103 laboratory-confirmed cases and 1 probable case, which included 1 death, had been reported to the WHO as of June 17. The majority of cases in the current outbreak have been reported through sexual health or other health services in primary or secondary healthcare facilities, with a history of travel to Europe, the United States, or other countries rather than to nations where the virus was not previously known to exist, and increasingly recent local travel or no travel at all, as well as a history of travel. Males who have sex with other men who have lately reported having sex with new partners or many partners continue to be the main targets of the monkeypox outbreak. The WHO currently rates the worldwide risk as moderate considering.



Fig. 3 epidemiology of monkeypox virus

PATHOPHYSIOLOGY

The respiratory epithelium is first infected by the monkeypox virus, which then travels by the lymphomatous route to infect the main systemic organs and multiply there, showing initial viremia. Due to the body's reticuloendothelial system's effective removal of the virus during this stage, there was little to no virus found in the blood. Rash and mucosal lesions are caused by the virus when it is discharged from the infected organs and lymphoid tissues into the circulation and reaches the cornified layer of the skin. Secondary viremia occurs after primary viremia. Additionally, it should be emphasized that a load has a significant impact on how severe the exanthem and enanthem are. There has been a greater than 10-fold increase in confirmed, probable, and/or possible MPX cases over the past 5 decades, from 48 cases in the 1970s to 520 cases in the 1990s, with the DRC being the country that is most affected. In the first decade of the 2000s, MPX cases were only described in 3 countries in Africa but between 2010 and 2019, cases were reported in 7 African

countries, which were Cameroon, Central African Republic (CAR), DRC, Liberia, Nigeria, Sierra Leone, and Republic of the Congo. The collected data suggest that this trend represents actual disease increase and not merely a result of improved surveillance.

Smallpox was successfully eradicated, and there is limited need for medications that specifically target MPX due to the virus's rarity, remote location, and few reported cases. Antiviral screening tests conducted by the pharmaceutical industry as part of their drug discovery activities typically do not even include VAC. Recent occurrences have elevated the issue of bioterrorism to the top of the global public agenda. The development, licensing, and stockpiling of adequate supplies of antiviral medications capable of combating aggressive Orth poxviruses has now taken precedence. Smallpox patients have confluent lesions that are fluid-filled during the vesicular and pustular phases, which are gathered in the hypodermic region and subsequently ooze out during the crusting phase. It is important to note that shock can happen as these phases transition since a significant amount of intravascular volume has been lost. Similar to this, individuals with monkeypox infection in the US required volume replacement due to gastrointestinal fluid loss if they had signs of mucosal and gastrointestinal problems. The migration of fluid from the intravascular compartment to the extravascular compartment as a result of hypoalbuminemia and fluid loss in the gastrointestinal tract, as seen in systemic infections, is the fundamental process for volume replenishment. This shows that monkeypox infection exists.

It was discovered while researching the pathophysiology of smallpox that people who had the most serious type of smallpox—hemorrhagic smallpox—were probably suffering from disseminated intravascular coagulation. The two US patients from the monkeypox outbreak who developed hemorrhagic pustules were reported to have no signs of disseminated intravascular coagulation, but they did have mild thrombocytopenia.



Fig. 4 pathophysiology of monkeypox virus

IDENTIFICATION AND TREATMENT

Monkeypox infection is diagnosed by using a variety of techniques, including electron microscopy and immunohistochemistry, on the tissue removed from the lesion to look for the monkeypox virus. Since real-time PCR is a highly efficient and sensitive method for detecting viral DNA, it can also be used to track the virus in a sample. To determine previous exposure to an orthopoxvirus, whether through infection or vaccination, serological markers like antiorthopoxvirus IgM and IgG can be employed. Since the monkeypox virus is widespread in rural regions without electricity, research should be done to create assays that can be examined in a very basic environment.[1]

A precise diagnosis is essential for keeping natural illness under control or in the early detection of a potential bioterrorism incident because the clinical picture of monkeypox is extremely similar to that of chickenpox and smallpox. Table 1 lists the evaluation standards for patients with monkeypox, chickenpox, or smallpox in the differential diagnosis. Although conditions like or and bovine stomatitis, which are caused by Para poxviruses and can result in localized skin lesions similar to those found in the US monkeypox outbreak, can do so, electron microscopy makes it simple to separate them from orthopoxviruses. Since there is no effective, approved antiviral therapy for monkeypox, quarantine and quick ring vaccination are the only viable public health preventative measures after the disease agent has been detected. Given how simple the final result of the smallpox eradication campaign was the complete eradication of the disease worldwide. Monkeypox cannot be completely eradicated since there is an animal reservoir for the disease. A high level of protection against MPXV infection is provided by immunization with the vaccinia virus (the smallpox vaccine). In reality, studies conducted in the 1960s demonstrated that smallpox vaccination may successfully immunize monkeys against monkeypox. Additionally, not only were there fewer cases of human monkeypox among those who received vaccinations in Africa, but many of the cases were also very mild (with few lesions), and some cases may have even been subclinical. Pre-exposure immunization is advised by the Centers for Disease Control and Prevention for anyone who are researching animals or Cases of human monkeypox, medical personnel caring for patients with monkeypox, anyone coming into touch with suspected MPXV-infected animals, and lab personnel handling potentially infected specimens are at risk. The Centers for Disease Control and Prevention advise immunization within 4 days of initial close contact with a confirmed case of monkeypox, but vaccination should be considered up to 14 days following exposure. Although vaccinia immune globulin is currently advised for treating progressive vaccinia, eczema vaccinate, and severe generalized vaccinia, there is currently no information available on its efficacy for treating human monkeypox. Immunoglobulin therapy may be beneficial for a patient with a severe MPXV infection; however, this is uncertain.[6] Tecovirimat and Brin cidofovir are the only therapies for monkeypox that are currently approved in the United States and Europe, respectively. By inhibiting the orthopoxviral protein p37, tecovirimat prevents viral transmission from cell to cell. Although tecovirimat has achieved full regulatory approval for the treatment of monkeypox, its usage for the treatment of smallpox is based on an experimental new drug application.

Symptomatic management and supportive care are the main management options available for patients with monkeypox infection at this time due to the lack of evidence-based treatments. Several substances, including cidofovir, which is used to treat a variety of viruses because it works by inhibiting DNA polymerase, have therapeutic potential against orthopoxvirus species. Since cidofovir has nephrotoxicity, CMX-001, an oral antiviral medicine that works by blocking DNA polymerase instead, is being developed as a modified version of this treatment. A separate medication that is taken orally, ST-246, prevents the release of internal viruses and has demonstrated promising efficacy against a variety of orthopoxvirus species, including variola virus. The monkeypox virus has also been effectively treated in nonhuman primates and small mammals. According to data, smallpox vaccination may have a protective effect against the monkeypox virus and may ameliorate the clinical symptoms of illness.[4]

In the UK in 2018, a single dose of Imvanex, a third-generation smallpox vaccine, was given as postexposure prophylaxis as an off-label indication to people at intermediate and high risk of contracting the monkeypox virus. This is because the smallpox vaccine confers cross-protection against monkeypox. Metal-based nanoparticles are utilized in biological systems in recent nanotechnology advancements in medical research. There are still a lot of unsolved questions about this complex technology. However, monkeypox plaque development was dramatically reduced by silver-containing nanoparticles with a 10 nm diameter (Ag-PS-10), which were found to be the most effective at reducing monkeypox virus infectivity.

The COVID-19 pandemic's impact on the healthcare system and the resurgence of monkeypox infection highlight a number of public health issues, particularly in low-resource nations. Although the smallpox vaccination offers some protection from monkeypox infection, the widespread discontinuation of it following the eradication of smallpox disease leaves many younger people vulnerable to infection. In fact, people under the age of 50 have been documented to have the majority of the current instances. However, tribes in the DRC that had had smallpox vaccinations had shown to have long-lasting immunity (>25 years) against monkeypox infection. This also shows an obvious double standard in light of the widespread concern for this illness. Despite the fact that monkeypox has continued to be an endemic issue in Central and West African nations, the lack of adequate healthcare resources for monitoring and once it spread to nations in the Global North, surveillance of this disease, which also faced interruption from conflict and climate change, was given international attention. The emergence of COVID-19 has sparked widespread deforestation, migration, conflict, and climate change. The expanding human population's encroachment into previously uninhabited habitats may pave the way for the reappearance of additional diseases and even drive their mutation into more virulent strains of previously benign infections, potentially making our current therapeutic interventions and vaccinations obsolete. To improve interaction with local communities, countries in the Global North must exchange improved diagnostic equipment and research with nations where monkeypox is endemic. When a more thorough One Health strategy is put into practice, research on vaccinations and therapeutic agents.

CONCLUSION

An infection called human monkeypox has the potential to spread through zoonotic reservoirs. Civil unrest and the ease of international travel appear to be the main factors driving the virus's dispersal in nonendemic regions. Other factors include human movement in animal reservoirs' natural habitats, which increases the risk of zoonoses and human contact with wildlife. To better understand the variety of factors related with illness transmission and spread, greater research is needed to address the most recent epidemic in the prevalence of human diseases. Current research should concentrate on epidemiological risk factors, animal reservoirs, and COVID-19 coinfection in endemic locations. At all incident sites around the world, control and prevention measures should be put in place, including education and personal hygiene. [7] The US outbreak proved that human monkeypox has the ability to spread via zoonotic reservoirs. Civil war and forced migration raise worries about the spread of the virus into a monkeypox-free region or about people moving to more heavily forested areas where they are more likely to come into contact with wildlife and a variety of zoonoses. To better comprehend the variety of elements involved in disease transmission and distribution, the recorded increase in the frequency of human disease requires deeper investigation and analysis.

Advances in our knowledge of this essential zoonosis will assist better direct prevention tactics and lessen human disease. There are still numerous mysteries concerning human disease, animal reservoirs, and the virus itself.

Regular genomic investigations, serological surveys, and evaluations for vaccination of health professionals and high-risk groups should all be done for monkeypox as part of normal disease surveillance protocols. Since monkeypox is no longer a rare condition, it is crucial to find African animals that are home to orthopoxviruses, improve the algorithm for determining the clinical spectrum and severity of monkeypox, and evaluate the risk of transmission in relation to various types of contact with clinical cases. For it to be contained, immediate and proactive action will be essential. The secret to success will be making sure that we take lessons from recent epidemics and soon and early disseminate the tools that are available. The signs that monkeypox could become a major public health issue have been there for a while. Now is the time to implement a really global strategy that permanently resolves this issue in both wealthy and, crucially, endemic nations that have been combating monkeypox for decades.

REFERENCES

1. Durski KN, McCollum AM, Nakazawa Y, Petersen BW, Reynolds MG, Briand S, et al. Emergence of Monkeypox - West and Central Africa, 1970-2017. Mmwr. 2018; Morbidity and mortality weekly report. 67(10):306–10. pmid:29543790.
2. Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(37):16262–7. pmid:20805472.
3. Marennikova SS, Seluhina EM, Malceva NM, Ladnyj ID. Poxviruses isolated from clinically ill and asymptomalically infected monkeys and a chimpanzee. Bulletin of the World Health Organization. 1972;46(5):613–20. pmid:4340220.
4. Pv Magnus, Andersen EK Petersen KB, Birch-Andersen A. A Pox-like Disease in Cynomolgus Monkeys. Acta Pathologica Microbiologica Scandinavica. 1959;46(2):156–76.
5. Doty JB, Malekani JM, Kalemba LN, Stanley WT, Monroe BP, Nakazawa YU, et al. Assessing Monkeypox Virus Prevalence in Small Mammals at the Human-Animal Interface in the Democratic Republic of the Congo. Viruses. 2017;9(10):03. pmid:28972544.
6. Hutin YJ, Williams RJ, Malfait P, Pebody R, Loparev VN, Ropp SL, et al. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerging Infectious Diseases. 2001;7(3):434–8. pmid:11384521.
7. Khodakevich L, Jezek Z, Messinger D. Monkeypox virus: ecology and public health significance. Bulletin of the World Health Organization. 1988;66(6):747–52. pmid:2853010.
8. Reynolds MG, Carroll DS, Olson VA, Hughes C, Galley J, Likos A, et al. A silent enzootic of an orthopoxvirus in Ghana, West Africa: Evidence for multi-species involvement in the absence of widespread human disease. American Journal of Tropical Medicine and Hygiene. 2010;82(4):746–54. pmid:20348530.
9. Jezek Z, Szczeniowski M, Paluku KM, Mutombo M. Human monkeypox: clinical features of 282 patients. Journal of Infectious Diseases. 1987;156(2):293–8. pmid:3036967.
10. Mbala PK, Huggins JW, Riu-Rovira T, Ahuka SM, Mulembakani P, Rimoin AW, et al. Maternal and Fetal Outcomes among Pregnant Women with Human Monkeypox Infection in the Democratic Republic of Congo. Journal of Infectious Diseases. 2017;216(7):824–8. pmid:29029147.
11. Withers MR, Kingebeni PM, Muyembe JJT, Martin J, Riu-Rovira T, Huggins J, et al. Outcome of four pregnancies in congolese women with monkeypox infection. American Journal of Tropical Medicine and Hygiene. 2011;1):397. pmid:71043487.
12. Kisalu NK, Mokili JL. Toward Understanding the Outcomes of Monkeypox Infection in Human Pregnancy. Journal of Infectious Diseases. 2017;216(7):795–7. pmid:29029238
13. Fine PE, Jezek Z, Grab B, Dixon H. The transmission potential of monkeypox virus in human populations. International Journal of Epidemiology. 1988;17(3):643–50. pmid:2850277.

14. Heymann DL, Szczeniowski M, Esteves K. Re-emergence of monkeypox in Africa: a review of the past six years. British Medical Bulletin. 1998;54(3):693–702. pmid:10326294.
15. Meyer H, Perrichot M, Stemmler M, Emmerich P, Schmitz H, Varaine F, et al. Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. Journal of Clinical Microbiology. 2002;40(8):2919–21. pmid:12149352.
16. Mutombo M, Arita I, Jezek Z. Human monkeypox transmitted by a chimpanzee in a tropical rain-forest area of Zaire. Lancet. 1983;1(8327):735–7. Epub 1983/04/02. pmid:6132084.
17. Reynolds MG, Yorita KL, Kuehnert MJ, Davidson WB, Huhn GD, Holman RC, et al. Clinical manifestations of human monkeypox influenced by route of infection. Journal of Infectious Diseases. 2006;194(6):773–80. pmid:16941343.
18. Jezek Z, Grab B, Paluku KM, Szczeniowski MV. Human monkeypox: Disease pattern, incidence and attack rates in a rural area of northern Zaire. Tropical and Geographical Medicine. 1988;40(2):73–83. pmid:2841783.
19. Kile JC, Fleischauer AT, Beard B, Kuehnert MJ, Kanwal RS, Pontones P, et al. Transmission of monkeypox among persons exposed to infected prairie dogs in Indiana in 2003. Archives of Pediatrics and Adolescent Medicine. 2005;159(11):1022–5. pmid:16275790.
20. Hoff N, Mulembakani PM, Johnston SC, Kisalu NK, Muyembe JJ, Hensley LE, et al. Risk factors associated with human monkeypox in the democratic republic of Congo. American Journal of Tropical Medicine and Hygiene. 2014;1):199–200. pmid:71691886.
21. Nolen LD, Osadebe L, Katomba J, Likofata J, Mukadi D, Monroe B, et al. Extended human-to-human transmission during a monkeypox outbreak in the Democratic Republic of the Congo. Emerging Infectious Diseases. 2016;22(6):1014–21. pmid:27191380.
22. Hoff NA, Kebela-Ilunga B, Eckhoff P, Mukadi P, Mossoko M, Muyembe-Tamfum JJ, et al. A descriptive and quantitative analysis of potential underestimation of human monkeypox cases in the passive surveillance system in the democratic republic of congo. American Journal of Tropical Medicine and Hygiene. 2015;93 (4 Supplement):242. pmid:613370358.
23. Mukinda VB, Mwema G, Kilundu M, Heymann DL, Khan AS, Esposito JJ. Re-emergence of human monkeypox in Zaire in 1996. Monkeypox Epidemiologic Working Group. Lancet. 1997;349(9063):1449–50. pmid:9164323.
24. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, et al. The Detection of Monkeypox in Humans in the Western Hemisphere. New England Journal of Medicine. 2004;350(4):342–50. pmid:14736926.
25. Nakazawa Y, Emerson GL, Carroll DS, Zhao H, Li Y, Reynolds MG, et al. Phylogenetic and ecologic perspectives of a monkeypox outbreak, southern Sudan, 2005. Emerging Infectious Diseases. 2013;19(2):237–45. pmid:23347770.
26. Kugelman JR, Johnston SC, Mulembakani PM, Kisalu N, Lee MS, Koroleva G, et al. Genomic variability of monkeypox virus among humans, Democratic Republic of the Congo. Emerging Infectious Diseases. 2014;20(2):232–9. pmid:24457084.
27. Kalthan E, Tenguere J, Ndjapou SG, Koyazengbe TA, Mbomba J, Marada RM, et al. Investigation of an outbreak of monkeypox in an area occupied by armed groups, Central African Republic. Medecine et Maladies Infectieuses. 2018;48(4):263–8. pmid:29573840.
28. McCollum AM, Nakazawa Y, Ndongala GM, Pukuta E, Karhemere S, Lushima RS, et al. Human monkeypox in a conflict region of the democratic republic of the Congo. American Journal of Tropical Medicine and Hygiene. 2013;1):17–8. pmid:71311889.
29. Nakoune E, Selekon B, Komoyo GF, Kazanji M, Garba-Ouangole SM, Janssens C, et al. A Nosocomial Outbreak of Human Monkeypox in the Central African Republic. Open Forum Infectious Diseases. 2017;4(4). pmid:29732376.
30. Breman JG, Nakano JH, Coffi E, Godfrey H, Gautun JC. Human poxvirus disease after smallpox eradication. American Journal of Tropical Medicine & Hygiene. 1977;26(2):273–81. pmid:192091.
31. Laudisoit A, Baelo P, Mussaw Awazi M, VanHoutte N, VanHees M, Amundala N, et al. Biodiversity, Bushmeat and Monkeypox in the Democratic Republic of the Congo: Another viral threat upon larger cities? Tropical Medicine and International Health. 2015;1):30–1. pmid:72054277.
32. Laudisoit A, Verheyen E, Baelo P, Akonda I, Nebesse C, Ngoy S, et al. A One Health team to improve Monkeypox virus outbreak response: An example from the Democratic Republic of the Congo. Tropical Medicine and International Health. 2017;22 (Supplement 1):53. pmid:618977852.
33. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Medicine. 2009;6(7):e1000097. pmid:19621072.
34. MacNeil A, Reynolds MG, Carroll DS, Karem K, Braden Z, Lash R, et al. Monkeypox or varicella? lessons from a rash outbreak investigation in the republic of the congo. American Journal of Tropical Medicine and Hygiene. 2009;80(4):503–7. pmid:19346366.
35. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, et al. The Detection of Monkeypox in Humans in the Western Hemisphere. New England Journal of Medicine. 2004;350(4):342–50. pmid:14736926.